120 related articles for article (PubMed ID: 20541921)
1. Quantitative prediction of MHC-II binding affinity using particle swarm optimization.
Zhang W; Liu J; Niu Y
Artif Intell Med; 2010 Oct; 50(2):127-32. PubMed ID: 20541921
[TBL] [Abstract][Full Text] [Related]
2. A Bayesian regression approach to the prediction of MHC-II binding affinity.
Zhang W; Liu J; Niu YQ; Wang L; Hu X
Comput Methods Programs Biomed; 2008 Oct; 92(1):1-7. PubMed ID: 18562039
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of peptide-MHC class II interaction.
Fleckenstein B; Jung G; Wiesmüller KH
Semin Immunol; 1999 Dec; 11(6):405-16. PubMed ID: 10625594
[TBL] [Abstract][Full Text] [Related]
4. In silico prediction of peptide-MHC binding affinity using SVRMHC.
Liu W; Wan J; Meng X; Flower DR; Li T
Methods Mol Biol; 2007; 409():283-91. PubMed ID: 18450008
[TBL] [Abstract][Full Text] [Related]
5. Immunodominance does not result from peptide competition for MHC class II presentation.
Lo-Man R; Langeveld JP; Martineau P; Hofnung M; Meloen RH; Leclerc C
J Immunol; 1998 Feb; 160(4):1759-66. PubMed ID: 9469434
[TBL] [Abstract][Full Text] [Related]
6. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.
Patel DM; Arnold PY; White GA; Nardella JP; Mannie MD
J Immunol; 1999 Nov; 163(10):5201-10. PubMed ID: 10553040
[TBL] [Abstract][Full Text] [Related]
7. Contrasting efficacy of presentation by major histocompatibility complex class I and class II products when peptides are administered within a common protein carrier, self immunoglobulin.
Zaghouani H; Kuzu Y; Kuzu H; Brumeanu TD; Swiggard WJ; Steinman RM; Bona CA
Eur J Immunol; 1993 Nov; 23(11):2746-50. PubMed ID: 8223850
[TBL] [Abstract][Full Text] [Related]
8. Peptide binding by class I and class II MHC molecules.
Batalia MA; Collins EJ
Biopolymers; 1997; 43(4):281-302. PubMed ID: 9316393
[TBL] [Abstract][Full Text] [Related]
9. Identification of T helper epitopes from prostatic acid phosphatase.
McNeel DG; Nguyen LD; Disis ML
Cancer Res; 2001 Jul; 61(13):5161-7. PubMed ID: 11431355
[TBL] [Abstract][Full Text] [Related]
10. Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites.
Rajnavölgyi E; Horváth A; Gogolák P; Tóth GK; Fazekas G; Fridkin M; Pecht I
Eur J Immunol; 1997 Dec; 27(12):3105-14. PubMed ID: 9464794
[TBL] [Abstract][Full Text] [Related]
11. Predicting peptides bound to I-Ag7 class II histocompatibility molecules using a novel expectation-maximization alignment algorithm.
Chang KY; Suri A; Unanue ER
Proteomics; 2007 Feb; 7(3):367-77. PubMed ID: 17211830
[TBL] [Abstract][Full Text] [Related]
12. Toward prediction of class II mouse major histocompatibility complex peptide binding affinity: in silico bioinformatic evaluation using partial least squares, a robust multivariate statistical technique.
Hattotuwagama CK; Toseland CP; Guan P; Taylor DJ; Hemsley SL; Doytchinova IA; Flower DR
J Chem Inf Model; 2006; 46(3):1491-502. PubMed ID: 16711768
[TBL] [Abstract][Full Text] [Related]
13. EpiTOP--a proteochemometric tool for MHC class II binding prediction.
Dimitrov I; Garnev P; Flower DR; Doytchinova I
Bioinformatics; 2010 Aug; 26(16):2066-8. PubMed ID: 20576624
[TBL] [Abstract][Full Text] [Related]
14. Comparison of structural requirements for interaction of the same peptide with I-Ek and I-Ed molecules in the activation of MHC class II-restricted T cells.
Leighton J; Sette A; Sidney J; Appella E; Ehrhardt C; Fuchs S; Adorini L
J Immunol; 1991 Jul; 147(1):198-204. PubMed ID: 1711074
[TBL] [Abstract][Full Text] [Related]
15. Class II HLA-peptide binding prediction using structural principles.
Mohanapriya A; Lulu S; Kayathri R; Kangueane P
Hum Immunol; 2009 Mar; 70(3):159-69. PubMed ID: 19187794
[TBL] [Abstract][Full Text] [Related]
16. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
[TBL] [Abstract][Full Text] [Related]
17. Prediction of peptide binding to major histocompatibility complex class II molecules through use of boosted fuzzy classifier with SWEEP operator method.
Takahashi H; Honda H
J Biosci Bioeng; 2006 Feb; 101(2):137-41. PubMed ID: 16569609
[TBL] [Abstract][Full Text] [Related]
18. Prediction of MHC class II binders using the ant colony search strategy.
Karpenko O; Shi J; Dai Y
Artif Intell Med; 2005; 35(1-2):147-56. PubMed ID: 16061368
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule.
Takeshita T; Takahashi H; Kozlowski S; Ahlers JD; Pendleton CD; Moore RL; Nakagawa Y; Yokomuro K; Fox BS; Margulies DH
J Immunol; 1995 Feb; 154(4):1973-86. PubMed ID: 7530749
[TBL] [Abstract][Full Text] [Related]
20. [MHC tetramers: tracking specific immunity].
Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
